21:39
“How I treat” based on the new/updated classification systems
24:49
How I treat” a patient with lower-risk MDS showing signs of ESA failure
04:12
What does data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?
27:43
Quality of life assessment and transfusion-free survival
13:22
How can structural variant assessment assist in MRD assessment in MDS?
31:15
The challenges of measuring overall survival in elderly patients with MDS.
11:00
How do we differentiate high-risk MDS from AML?
08:56
How do we treat high-risk patients outside of a clinical trial?
36:27
What factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?
08:06
How could venetoclax combinations improve outcome in high-risk MDS?
20:33
Sequence of therapy in myelodysplastic syndromes
05:39
Highlights of the 8th Translational Research Conference: Myelodysplastic Syndromes
11:45
MDS International Guidelines 2022
08:38
Hot topics relevant to MDS
07:57
What does the FIGARO trial reveal about predictors of outcome post-transplant?
13:13
Can IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?
04:59
Do mRNA-based COVID vaccines lead to adverse events in recently transplanted patients?
07:17
New clinical advances in MDS risk categorization
19:36
How can the hematologic toxicities with Ven+Aza be managed more effectively?
07:33
What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be manag...
08:40
What new treatments are available for high-risk MDS? What does this mean for patients?
04:20
What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?
06:14
How successful is CPX-351 as first-line treatment for MDS?
06:06
What new developments are there in the treatment of relapsed or refractory MDS?
04:09
Should novel agents be used prior to transplant in MDS-EB1/2?
04:02
How can we predict drug resistance in high-risk MDS?
04:24
What are the priority challenges in MDS treatment?
05:04
What treatment would you suggest for high risk MDS patients not fit for chemotherapy or HSCT?
05:39
How have oral hypomethylating agents changed the management of MDS?
11:30
How can we tailor treatment to improve outcome in MDS?
06:28
Highlights of EHA 2021
04:01
What baseline factors affect QoL in MDS? How do these change with treatment?
05:11
Which subgroups of patients benefit most from a Ven+Aza combination?
05:47
How should molecular profiling be used to guide MDS therapy?
04:14
How can immunotherapy be used in MDS?
03:36
What are the new approaches for anemia treatment in MDS?
02:38
Is CAR-T an option for patients with MDS?
03:29
What is new for MDS with del(5q)?
05:01
How does COVID-19 infection affect hematopoiesis in MDS?
11:15
How can we tailor treatment to improve outcome in MDS?
02:33
What are novel strategies to treat low-risk MDS?
02:05
Phase III Dacota trial: Will hydroxyurea remain SoC for advanced proliferative CMML?
11:34
How should we manage HMA failure?
08:27
What are novel therapeutic approaches in MDS?
06:27
What are novel strategies to treat higher-risk MDS?
10:20
Is there a place for immunotherapy in MDS?
02:16
Can changes in DNA methylation pattern predict the response to HMA in MDS?
01:58
Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?
02:03
How can we improve on current risk stratification in MDS?
05:48
What is the clinical impact of DDX41 mutations in myeloid neoplasms?
03:04
P-2001 study: Which patients benefit most from pevonedistat plus azacitidine?
05:45
Why is TIM3 a good target for treating patients with high-risk MDS?
02:10
When should we consider allo-SCT for patients with MDS?
04:14
What are the challenges in diagnosing MDS?
03:49
How can cytogenetics predict response to venetoclax and azacitidine in MDS?
05:51
Practice-changing abstracts at EHA 2020
02:33
What are the challenges in assessing response to treatment in MDS?
03:00
What are the new approaches for anemia in MDS?
04:23
What is the relationship between the SF3B1 splicing mutation and therapy-related MDS?
08:32
Is there synergy between anti-TIM-3 therapy and HMAs in the treatment of MDS?
X
About
Tags